Defining disease modification in myelofibrosis in the era of targeted therapy

The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what const...

Descripción completa

Detalles Bibliográficos
Autores principales: Pemmaraju, Naveen, Verstovsek, Srdan, Mesa, Ruben, Gupta, Vikas, Garcia, Jacqueline S., Scandura, Joseph M., Oh, Stephen T., Passamonti, Francesco, Döhner, Konstanze, Mead, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322520/
https://www.ncbi.nlm.nih.gov/pubmed/35499819
http://dx.doi.org/10.1002/cncr.34205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322520/
https://www.ncbi.nlm.nih.gov/pubmed/35499819
http://dx.doi.org/10.1002/cncr.34205

Ejemplares similares